Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019

Description: About Acquired Orphan Blood Diseases Therapeutics
Acquired orphan blood diseases are rare disorders and are characterized by the body's inability to produce a sufficient amount of RBCs. This is basically because of the improper functioning of bone marrow to produce RBCs in the blood. This leads to a decrease in platelet counts, which can eventually lead to anemia and thrombosis. The acquired orphan blood diseases are developed in the blood after the post fetal life; they are not caused because of genetic reasons. The major orphan blood diseases that contribute to acquired orphan blood diseases are the following: ITP, MDS, MF PNH, and PV.

The analysts forecast the Global Acquired Orphan Blood Diseases Therapeutics market to grow at a CAGR of 12.29 percent over the period 2014-2019.

Covered in this Report
This report covers the present scenario and the growth prospects of the Global Acquired Orphan Blood Diseases Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sale of marketed drugs used in the treatment of PNH, ITP, PV, MF, and MDS.

The report, the Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Acquired Orphan Blood Diseases Therapeutics market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions
- Americas
- APAC
- EMEA

Key Vendors
- Alexion Pharmaceuticals
- Amgen
- Celgene
- F. Hoffmann-La Roche
- GlaxoSmithKline
- Incyte

Other Prominent Vendors
- Cyclacel Pharmaceuticals
- CTI Biopharma (Cell Therapeutics)
- Eli Lilly
- Gilead Sciences
- Onconova Therapeutics
- MebVax Therapeutics
- Novartis
- Sanofi
- Shire Pharmaceuticals
- S* Bio Pte

Market Drivers
- Exemption from Pricing Obstacle
- For a full, detailed list, view our report

Market Challenges
- Companies Hesitant to Invest in Rare Diseases Therapeutics
- For a full, detailed list, view our report

Market Trends
- Benefit from Untapped Market
- For a full, detailed list, view our report

Key Questions Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key Market Trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Contents:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Product Profiles
04.1 Soliris
04.2 Nplate
04.3 Revlimid
04.4 Vidaza
04.5 Promacta
04.6 Jakafi
04.7 Rituxan
05. Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06. Introduction
07. Diseases Overview
07.1 ITP
07.1.1 Understanding the Disease
07.1.2 Epidemiology
07.1.3 Etiology
07.1.4 Pathophysiology
07.1.5 Management of Disease
07.2 MDS
07.2.1 Understanding the Disease
07.2.2 Epidemiology
07.2.3 Etiology
07.2.4 Pathophysiology
07.2.5 Management of Disease
07.3 MF
07.3.1 Understanding the Disease
07.3.2 Epidemiology
07.3.3 Etiology
07.3.4 Pathophysiology
07.3.5 Management of Disease
07.4 PNH
07.4.1 Understanding the Disease
07.4.2 Epidemiology
07.4.3 Etiology
07.4.4 Pathophysiology
07.4.5 Management of Disease
07.5 PV
07.5.1 Understanding the Disease
07.5.2 Epidemiology
07.5.3 Etiology
07.5.4 Pathophysiology
07.5.5 Management of Disease
07.6 Pipeline Analysis
07.7 Emerging Treatment Options
08. Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis
09. Market Segmentation by Indication Type
09.1.1 Market Size and Forecast for ITP
09.1.2 Market Size and Forecast for MDS
09.1.3 Market Size and Forecast for MF
09.1.4 Market Size and Forecast for PNH
09.1.5 Market Size and Forecast for PV
10. Geographical Segmentation
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2014
18.2.1 Competitive Assessment of Top Drugs
18.2.2 Alexion Pharmaceuticals
18.2.3 Amgen
18.2.4 Celgene
18.2.5 F. Hoffmann-La Roche
18.2.6 GlaxoSmithKline
18.2.7 Incyte
Other Prominent Vendors
19. Key Vendor Analysis
19.1 F. Hoffmann-La Roche Ltd.
19.1.1 Key Facts
19.1.2 Business Overview
19.1.3 Business Segmentation
19.1.4 Business Segmentation by Revenue 2012 and 2013
19.1.5 Sales by Geography
19.1.6 Business Strategy
19.1.7 Key Information
19.1.8 SWOT Analysis
19.2 Celgene
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Business Strategy
19.2.4 Business Segmentation by Revenue
19.2.5 Sales by Geography
19.2.6 Key Information
19.2.7 SWOT Analysis
19.3 Alexion
19.3.1 Key Facts
19.3.2 Business Overview
19.3.3 Geographical Segmentation by Revenue 2013
19.3.4 Business Strategy
19.3.5 Recent Developments
19.3.6 SWOT Analysis
19.4 Amgen
19.4.1 Key Facts
19.4.2 Business Overview
19.4.3 Business Segmentation by Revenue 2013
19.4.4 Product Portfolio by Revenue 2013
19.4.5 Business Segmentation by Revenue 2012 and 2013
19.4.6 Geographical Segmentation by Revenue 2013
19.4.7 Business Strategy  
19.4.8 Recent Developments  
19.4.9 SWOT Analysis  
19.5 Incyte  
19.5.1 Key Facts  
19.5.2 Business Overview  
19.5.3 Revenue Segmentation by 2013  
19.5.4 Revenue Segmentation by 2012 and 2013  
19.5.5 Geographical Segmentation  
19.5.6 Business Strategy  
19.5.7 Recent Developments  
19.5.8 SWOT Analysis  
19.6 GlaxoSmithKline  
19.6.1 Key Facts  
19.6.2 Business Overview  
19.6.3 Business Segmentation  
19.6.4 Business Segmentation by Revenue 2012 and 2013  
19.6.5 Sales by Geography  
19.6.6 Pipeline Products  
19.6.7 Business Strategy  
19.6.8 Key Information  
19.6.9 SWOT Analysis  
19.6.10 Strengths  
19.6.11 Weaknesses  
19.6.12 Opportunities  
19.6.13 Threats

20. Other Reports in this Series

List of Exhibits  
Exhibit 1: Market Research Methodology  
Exhibit 2: Snapshot of ITP  
Exhibit 3: Snapshot of MDS  
Exhibit 4: Snapshot of MF  
Exhibit 5: Snapshot of PNH  
Exhibit 6: Snapshot of PV  
Exhibit 8: Global Acquired Orphan Blood Diseases Therapeutics Market Segmentation by Indication Type  
Exhibit 9: Global Acquired Orphan Blood Diseases Therapeutics Market Revenue Comparison by Indication, 2014 and 2019 (US$ million)  
Exhibit 10: Global Acquired Orphan Blood Diseases Therapeutics Market Percent Share by Indication, 2014 and 2019  
Exhibit 16: Geographical Segmentation of Global Acquired Orphan Blood Diseases Therapeutics Market in 2014  
Exhibit 17: Marketing Exclusivity for Orphan Drugs in Some Regions  
Exhibit 18: Revenue Comparison of Top Drugs for Acquired Orphan Blood Diseases Therapeutics market in 2013 (US$ million)  
Exhibit 19: Revenue Comparison and YoY Growth for Soliris from 2012-2014 (US$ million)  
Exhibit 20: Global Market Forecast for Soliris from 2014-2019 (US$ million)  
Exhibit 21: Revenue Comparison and YoY Growth for Nplate from 2011-2013 (US$ million)  
Exhibit 22: Revenue Comparison and YoY Growth for Revlimid from 2011-2013 (US$ million)  
Exhibit 23: Revenue Comparison and YoY Growth for Vidaza from 2011-2013 (US$ million)  
Exhibit 24: Revenue Comparison for Rituxan from 2012-2013 (US$ million)  
Exhibit 25: Revenue Comparison and YoY Growth for Promacta 2011-2014 (US$ million)  
Exhibit 26: Revenue Comparison for Jakafi from 2012-2013 (US$ million)  
Exhibit 27: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013  
Exhibit 28: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013  
Exhibit 29: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)  
Exhibit 30: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/3129432/">http://www.researchandmarkets.com/reports/3129432/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SCBR6CJV</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td>USD 3000</td>
</tr>
<tr>
<td>Single User</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users</td>
<td>USD 3500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>USD 4500</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>USD 1000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in **BLOCK CAPITALS**

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
</tr>
<tr>
<td>Last Name:</td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World